Wentworth CEO sees both capital and dividend growth opportunities in Tanzania's Mnazi gas field Watch Now

Less Ads, More Data, More Tools Register for FREE

TOP NEWS: GlaxoSmithKline Gets First Approval For Duvroq In Japan

Mon, 29th Jun 2020 09:03

(Alliance News) - GlaxoSmithKline PLC on Monday said its drug Duvroq had been given its first approval in Japan to treat anaemia caused by chronic kidney disease.

The Brentford-headquartered pharmaceutical firm said the Japan Ministry of Health, Labour & Welfare approved Duvroq, the brand name for daprodustat, to treat anaemia from chronic kidney disease.

Anaemia is common in chronic kidney disease patients, as the kidneys stop making enough of a hormone called erythropoietin, which is involved in prompting red blood call production.

Japanese approval was mostly based on a phase 3 programme, which was conducted in Japan and evaluated Duvroq in patients across the chronic kidney disease spectrum, including those not on dialysis.

The drug has not been approved anywhere outside of Japan but Glaxo said its ongoing phase 3 global programme, including the Ascend-D and Ascend-ND studies, will support further submissions worldwide.

Duvroq is taken only as a once-daily pill in dialysis and non-dialysis patients, unlike standard care which requires injections. In Japan, Duvroq will be distributed exclusively by Kyowa Kirin Co Ltd under the strategic commercialisation deal between the two companies announced in 2018.

Hal Barron, chief scientific officer & president of R&D at Glaxo, said: "The approval of Duvroq brings a new, convenient oral treatment option to nearly 3.5 million patients in Japan who have anaemia associated with renal disease. We are pleased with this first approval and look forward to sharing data from our ongoing phase III programme as we seek to help many more patients suffering with this disease around the world."

Shares in Glaxo were up 0.2% at 1,651.00 pence in London on Monday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News

GSK partners with Canada's Medicago to develop plant-based Covid-19 vaccine

(Sharecast News) - GlaxoSmithKline has teamed up with Canada's Medicago to develop a vaccine which its hopes will be ready for use in the first half of 2021.

7 Jul 20 16:59

Glaxo, Medicago Partner To Develop Covid-19 Vaccine Candidate

Glaxo, Medicago Partner To Develop Covid-19 Vaccine Candidate

7 Jul 20 16:18

Sunday newspaper round-up: Vouchers, Grocers, Boohoo

(Sharecast News) - Radical plans to give all adults £500 and children £250 in vouchers to spend in sectors of the economy worst hit by the Covid-19 crisis are being considered by the Treasury. The proposals, drawn up by the Resolution Foundation think tank, which has had recent talks with the Treasury about its ideas, are aimed at kickstarting economic recovery by triggering a highly targeted surge in spending. Under the plans the vouchers could only be spent in certain sectors, such as hospitality and "face to face" retail, as opposed to online. - Guardian

5 Jul 20 15:59

PRESS: GlaxoSmithKline And Sanofi Near GBP500 Million UK Vaccine Deal

PRESS: GlaxoSmithKline And Sanofi Near GBP500 Million UK Vaccine Deal

5 Jul 20 14:51

Login to your account

Don't have an account? Click here to register.